Global 9-valent Human Papillomavirus Vaccine Market Growth 2025-2031
Description
The global 9-valent Human Papillomavirus Vaccine market size is predicted to grow from US$ 5437 million in 2025 to US$ 9557 million in 2031; it is expected to grow at a CAGR of 9.9% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The 9-valent human papillomavirus (HPV) vaccine is a recombinant vaccine that protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These types are associated with over 90% of cervical cancers and the majority of other HPV-related anogenital and oropharyngeal cancers. The vaccine is made using virus-like particle (VLP) technology and is administered in 2- or 3-dose schedules, depending on age. It is the most comprehensive HPV vaccine to date and plays a key role in cervical cancer prevention programs worldwide.
United States market for 9-valent Human Papillomavirus Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for 9-valent Human Papillomavirus Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for 9-valent Human Papillomavirus Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key 9-valent Human Papillomavirus Vaccine players cover Merck Group, GSK, Wantai Biological Pharmacy, Zhifei Biological Products, Walvax Biotechnology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “9-valent Human Papillomavirus Vaccine Industry Forecast” looks at past sales and reviews total world 9-valent Human Papillomavirus Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected 9-valent Human Papillomavirus Vaccine sales for 2025 through 2031. With 9-valent Human Papillomavirus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 9-valent Human Papillomavirus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global 9-valent Human Papillomavirus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on 9-valent Human Papillomavirus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global 9-valent Human Papillomavirus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 9-valent Human Papillomavirus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 9-valent Human Papillomavirus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of 9-valent Human Papillomavirus Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
HPV6
HPV11
HPV16
HPV18
Others
Segmentation by Application:
Hospital
Health Center
Epidemic Prevention Station
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck Group
GSK
Wantai Biological Pharmacy
Zhifei Biological Products
Walvax Biotechnology
Beijing Health Guard Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global 9-valent Human Papillomavirus Vaccine market?
What factors are driving 9-valent Human Papillomavirus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 9-valent Human Papillomavirus Vaccine market opportunities vary by end market size?
How does 9-valent Human Papillomavirus Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The 9-valent human papillomavirus (HPV) vaccine is a recombinant vaccine that protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These types are associated with over 90% of cervical cancers and the majority of other HPV-related anogenital and oropharyngeal cancers. The vaccine is made using virus-like particle (VLP) technology and is administered in 2- or 3-dose schedules, depending on age. It is the most comprehensive HPV vaccine to date and plays a key role in cervical cancer prevention programs worldwide.
United States market for 9-valent Human Papillomavirus Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for 9-valent Human Papillomavirus Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for 9-valent Human Papillomavirus Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key 9-valent Human Papillomavirus Vaccine players cover Merck Group, GSK, Wantai Biological Pharmacy, Zhifei Biological Products, Walvax Biotechnology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “9-valent Human Papillomavirus Vaccine Industry Forecast” looks at past sales and reviews total world 9-valent Human Papillomavirus Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected 9-valent Human Papillomavirus Vaccine sales for 2025 through 2031. With 9-valent Human Papillomavirus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 9-valent Human Papillomavirus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global 9-valent Human Papillomavirus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on 9-valent Human Papillomavirus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global 9-valent Human Papillomavirus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 9-valent Human Papillomavirus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 9-valent Human Papillomavirus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of 9-valent Human Papillomavirus Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
HPV6
HPV11
HPV16
HPV18
Others
Segmentation by Application:
Hospital
Health Center
Epidemic Prevention Station
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck Group
GSK
Wantai Biological Pharmacy
Zhifei Biological Products
Walvax Biotechnology
Beijing Health Guard Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global 9-valent Human Papillomavirus Vaccine market?
What factors are driving 9-valent Human Papillomavirus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 9-valent Human Papillomavirus Vaccine market opportunities vary by end market size?
How does 9-valent Human Papillomavirus Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
102 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for 9-valent Human Papillomavirus Vaccine by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for 9-valent Human Papillomavirus Vaccine by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
